Table 4.
Comparison of the baseline characteristics and the pravastatin pharmacokinetic and pharmacodynamic data in relation to the SLCO1B1 521T > C single nucleotide polymorphism in paediatric cardiac transplant recipients on a regimen of triple immunosuppression
| Variable | SLCO1B1 521TT (n = 9) | SLCO1B1 521TC (n = 3) | Difference in means (95% CI) | P |
|---|---|---|---|---|
| Age (years) | 11.6 ± 4.1 | 11.2 ± 6.6 | −0.4 (−7.4, 6.7) | |
| Weight (kg) | 41.4 ± 19.0 | 31.4 ± 12.9 | −10.0 (−36.6, 16.7) | |
| Height (cm) | 140.8 ± 18.6 | 135.2 ± 22.9 | −5.6 (−34.6, 23.3) | |
| Body mass index (mg m−2) | 19.6 ± 5.2 | 16.7 ± 1.8 | −2.9 (−9.9, 4.1) | |
| Cyclosporin dose (mg) | 160 (135–300) | 250 (150–300) | ||
| Cyclosporin dose (mg kg−1) | 5.4 ± 2.0 | 7.6 ± 2.1 | 2.2 (−0.8, 5.2) | |
| Azathioprine dose (mg) | 46.3 (18.8–75) | 25 (25–75) | ||
| Azathioprine dose (mg kg−1) | 1.2 ± 0.1 | 1.2 ± 0.3 | 0.0 (−0.4, 0.5) | |
| Azathioprine morning dose (mg) | 21.88 (12.5–37.5) | 12.5 (12.5–50) | ||
| Pravastatin | ||||
| dose (mg kg−1) | 0.31 ± 0.17 | 0.35 ± 0.12 | 0.04 (−0.20, 0.29) | 0.701 |
| Cmax (ng ml−1) | 145.7 ± 89.8 | 78.0 ± 10.3 | −67.7 (−135.7, 0.3) | 0.055 |
| AUC(0,24 h) (ng ml−1 h) | 366.3 ± 223.5 | 137.8 ± 41.0 | −228.5 (−402.7, −54.3) | 0.016 |
| tmax (h) | 1.0 (0.5–2.0) | 1.0 (1.0–1.5) | 0.981 | |
| t1/2 (h) | 1.3 ± 0.4 | 0.9 ± 0.1 | −0.4 (−0.7, −0.1) | 0.015 |
| Change in cholesterol (mmol l−1)* | −1.1 ± 1.2 | −0.1 ± 0.3 | 1.0 (0.1, 2.0) | 0.037 |
| Change in cholesterol (%)* | −18.9 ± 17.6 | −1.2 ± 5.8 | 17.7 (1.9, 32.1) | 0.031 |
| Change in LDL-cholesterol (mmol l−1)* | −1.0 ± 0.8 | −0.2 ± 0.3 | 0.8 (0.1, 1.5) | 0.022 |
| Change in LDL-cholesterol (%)* | −33.5 ± 20.8 | −7.7 ± 7.7 | 25.8 (7.4, 44.2) | 0.011 |
| Change in HDL-cholesterol (mmol l−1)* | 0.0 ± 0.4 | 0.4 ± 0.2 | 0.4 (0.1, 0.7) | 0.032 |
| Change in HDL-cholesterol (%)* | 0.4 ± 23.0 | 36.0 ± 15.6 | 35.6 (10.0, 62.7) | 0.026 |
| Change in triglycerides (mmol l−1)* | −0.1 ± 0.8 | −0.6 ± 0.6 | −0.5 (−1.6, 0.7) | 0.358 |
| Change in triglycerides (%)* | −2.5 ± 39.0 | −27.1 ± 15.1 | −24.6 (−59.5, 10.2) | 0.149 |
Data are mean ± SD; cyclosporin dose (mg), azathioprine doses (mg) and tmaxare median (range).
*
The change from baseline at 2 months with pravastatin 10 mg day−1.